Results 351 to 360 of about 87,437 (368)

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Lancet, The, 2009
Andrés José Maria Ferreri, Reni Michele, Alberto Fabbri   +2 more
exaly  

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia

Expert Opinion on Pharmacotherapy, 2017
T. Murphy, K. Yee
semanticscholar   +1 more source

Clofarabine and Cytarabine Combination in Patients with Fludarabine/Cytarabine Refractory Acute Myeloid Leukemia

Clinical Lymphoma Myeloma and Leukemia, 2016
Kaya, Ali Hakan, Sari, Hakan İsmail, ALTUNTAŞ, FEVZİ, Kızıl, Merih, Bekdemir, Filiz, Dal, Mehmet Sinan, DOĞU, MEHMET HİLMİ, CİVRİZ BOZDAĞ, SİNEM, Tekgunduz, Emre   +8 more
openaire   +3 more sources

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Lancet Oncology, The, 2015
Farhad Ravandi, Jeffrey E Lancet, Norbert Vey   +2 more
exaly  

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Cancer, 2007
Alan K Burnett, Robert K Hills
exaly  

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Nature Network Boston, 2016
C. Schneider, T. Oellerich, H. Baldauf, S. Schwarz, Dominique Thomas, R. Flick, H. Bohnenberger, L. Kaderali, Lena Stegmann, Anjali Cremer, Margarethe Martin, J. Lohmeyer, M. Michaelis, V. Hornung, C. Schliemann, W. Berdel, W. Hartmann, E. Wardelmann, F. Comoglio, M. Hansmann, A. Yakunin, G. Geisslinger, P. Ströbel, N. Ferreirós, H. Serve, O. Keppler, J. Cinatl   +26 more
semanticscholar   +1 more source

Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

Journal of Clinical Oncology, 2004
David L Chin, Jacob M Rowe
exaly  

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Lancet Haematology,the, 2019
Farhad Ravandi, Naval G Daver, Christopher B Benton   +2 more
exaly  

Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia

Journal of Clinical Oncology, 2008
Apostolia Maria Tsimberidou, William G Wierda, Razelle Kurzrock   +2 more
exaly  

Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461

Journal of Clinical Oncology, 2004
John C Byrd, Krzysztof Mrózek, Richard A Larson   +2 more
exaly